Eczacıbaşı Acquires Gensenta

Eczacıbaşı Acquires Gensenta Eczacıbaşı has completed a strategically significant acquisition in the pharmaceutical sector for Turkish and international markets. Eczacıbaşı has acquired Gensenta, which is owned by Amgen, a leading U.S. pharmaceutical company. The company will pay 135 million dollars for 99.96 percent of Gensenta. According to the announcement, the company has agreed to acquire 99.96 percent of Gensenta, owned by Amgen, a leading U.S. pharmaceutical company, for 135 million dollars. With the Gensenta acquisition, Eczacıbaşı will take another step toward becoming a major player in Turkish and international markets. The acquisition will be completed following approval by the Competition Board. Bülent Eczacıbaşı, Chairman of the Board of Eczacıbaşı Holding, noted that they have made an important investment in the healthcare sector with the Gensenta acquisition, stating: "As an organization committed to being a pioneer in modern, quality and healthy living both in Turkey and in international markets, we plan to expand our operations with a wide range of products and innovative pharmaceuticals in different treatment areas. With this acquisition, we continue to grow with the strength of domestic production by adding pharmaceutical and biosimilar drug manufacturing, pharmaceutical active ingredients production and healthcare export competencies to our portfolio," he said. Meanwhile, according to information provided by Amgen, following the strategic decision regarding the sale of Gensenta, operations in Turkey will continue and services to patients will be maintained.

Healthcare growth through exports

Gensenta is among Turkey's established companies in the pharmaceutical sector. The company, which began operations as a laboratory in 1923 and conducted extensive work in the sector as Mustafa Nevzat İlaç from 1957 onwards, was acquired in 2012 by Amgen, a U.S. biotechnology company among the world's leading firms. The company's name was changed to Gensenta in 2020. The company, which exports to different countries, was twice an export champion in the sector in recent years. As of end of 2021, the company realized 47 percent of its revenue through exports, and will provide an important contribution to Eczacıbaşı Group's export and international growth strategy in the healthcare sector. With its team of approximately 800 experts and modern facilities, Gensenta ranks among Turkey's significant finished pharmaceutical and pharmaceutical active ingredient producers. Gensenta is noted as a major lyophilized vial producer and exporter for Turkey and the region. Penicillin group, etodolac and other pharmaceutical active ingredients are produced at Gensenta Raw Material Production Facilities. With the Gensenta acquisition agreement in the healthcare sector, Eczacıbaşı will continue to provide pharmaceuticals produced with modern technology and new and comprehensive solutions to public health both domestically and in numerous countries abroad. Eczacıbaşı-Monrol, an important pillar of Eczacıbaşı's holistic health approach, aims to transfer its expertise in nuclear medicine to oncology, alongside high-quality radiopharmaceuticals produced with EU-GMP quality and targeted therapy products. Eczacıbaşı-Monrol's products are used in clinical trials for innovative treatment methods at renowned cancer centers around the world. Eczacıbaşı Pharmaceutical Marketing continues its work within the framework of strategies to enter selected new fields and to expand its product portfolio for public health.